VOLUME 9 (2018)
Table of Contents
News
|
| VATPase in cancer progression: Two sides of the same coin |
|
https://doi.org/10.18632/oncotarget.26218
|
| 35197-35198 |
|
| Clinical application of cfDNA: moving in the right direction but still a long way to go |
|
https://doi.org/10.18632/oncotarget.26224
|
| 35199-35200 |
Editorial
|
| Mutant molecular chaperone activates cytokine receptor as a homomultimer |
|
https://doi.org/10.18632/oncotarget.26221
|
| 35201-35202 |
|
| ASXL1 as a critical regulator of epigenetic marks and therapeutic potential of mutated cells |
|
https://doi.org/10.18632/oncotarget.26230
|
| 35203-35204 |
|
| Rise of the specialized oncoribosomes |
|
https://doi.org/10.18632/oncotarget.26231
|
| 35205-35206 |
Research Papers
|
| Biothiols and oxidative stress markers and polymorphisms of <i>TOMM40</i> and <i>APOC1</i> genes in Alzheimer's disease patients |
|
https://doi.org/10.18632/oncotarget.26184
|
| 35207-35225 |
|
| The potent and selective cyclindependent kinases 4 and 6 inhibitor ribociclib LEE011 is a versatile combination partner in preclinical cancer models |
|
https://doi.org/10.18632/oncotarget.26215
|
| 35226-35240 |
|
| Immortalized murine fibroblast cell lines are refractory to reprogramming to pluripotent state |
|
https://doi.org/10.18632/oncotarget.26235
|
| 35241-35250 |
Clinical Research Papers
|
| Integration of stereotactic radiotherapy in the treatment of metastatic colorectal cancer patients: a real practice study with longterm outcome and prognostic factors |
|
https://doi.org/10.18632/oncotarget.25834
|
| 35251-35265 |
Reviews
|
| Chemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors |
|
https://doi.org/10.18632/oncotarget.26186
|
| 35266-35277 |
Case Reports
|
| ROS1rearranged putative lung adenocarcinoma presenting as carcinoma of unknown primary site: a case report |
|
https://doi.org/10.18632/oncotarget.26233
|
| 35278-35282 |
Corrections
|
| Correction: Tumor driven by gainoffunction HER2 H878Y mutant is highly sensitive to HER2 inhibitor |
|
https://doi.org/10.18632/oncotarget.26252
|
| 35283-35283 |
|
| Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.26254
|
| 35284-35284 |
|
| Correction: EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy IPHC complete treatment |
|
https://doi.org/10.18632/oncotarget.26255
|
| 35285-35285 |
Errata
|
| Erratum: Functional analysis of MKP1 and MKP2 in breast cancer tamoxifen sensitivity |
|
https://doi.org/10.18632/oncotarget.26258
|
| 35286-35286 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
